Molecular approaches to personalizing management of ovarian cancer.
about
Confronting the Care Delivery Challenges Arising from Precision MedicineNew perspectives on targeted therapy in ovarian cancerA Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian CancerAdvances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.Effect of Pantethine on Ovarian Tumor Progression and Choline Metabolism.Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicityThe Importance of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers.Decitabine reactivated pathways in platinum resistant ovarian cancer.SurvNet: a web server for identifying network-based biomarkers that most correlate with patient survival data.Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II studyExperimental validation of methods for differential gene expression analysis and sample pooling in RNA-seq.Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.Midkine as a potential diagnostic marker in epithelial ovarian cancer for cisplatin/paclitaxel combination clinical therapy.'BRCAness' and its implications for platinum action in gynecologic cancer.Repopulation of ovarian cancer cells after chemotherapyPersonalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.Guizhi Fuling Wan, a Traditional Chinese Herbal Formula, Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Inactivation of the PI3K/AKT/mTOR PathwayVisANT 4.0: Integrative network platform to connect genes, drugs, diseases and therapiesMathematical models of breast and ovarian cancers.Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.Telodendrimer-based nanocarriers for the treatment of ovarian cancer.Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.Genetic changes in nonepithelial ovarian cancer.Involvement of autophagy in cervical, endometrial and ovarian cancer.Genetic markers for prediction of treatment outcomes in ovarian cancer.The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future.B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models.Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer.Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B.The role of biomarkers in the management of epithelial ovarian cancer.Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors.Using VisANT to Analyze Networks.Lysine-specific demethylase 1 (LSD1) destabilizes p62 and inhibits autophagy in gynecologic malignancies.Screening for ovarian cancer: imaging challenges and opportunities for improvement.Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer.LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer
P2860
Q26747282-B652570C-1DFC-46A1-8C55-708168E62390Q28082524-67069C93-F114-4A3C-B842-8F9924FA1F89Q28551341-FA058A9F-45CB-4E4F-B9F0-E9824F844A93Q30423597-4D7C7688-D36D-496D-A32D-F1422F59A271Q31145516-A91365B7-20F6-4CA1-9FA6-8F5733F3C32DQ33554192-E373180B-08E6-4217-AF7C-63900F6B981BQ33809605-0F59D003-FF2F-4919-9772-14D341F6B4AAQ33976957-96FB2EE9-9E76-4463-820B-D252E01A3082Q34262900-BAA3AABD-39C6-4C51-8172-B23DFC3EAFCFQ34354529-867D75E0-E123-4D54-B5B4-388957C1E1A5Q34486787-6F7EA99E-041D-4DD1-BCDD-3A4DF14F4287Q34662185-62861C2E-7977-4467-B808-63E8E78A1663Q35402367-003BE942-1DEA-4B55-AC98-E8D4D27ADC63Q36380704-1009E0A6-031F-45E9-A5C1-E5AF94D417FFQ36725453-88051524-84B9-4478-8DDF-661D06B242E6Q36817080-42207FA5-B532-4EC7-817C-0684364618F7Q36953023-B9C5221D-E5C8-4851-9787-2FC94FE85971Q36953937-EA01A97B-8055-4ECF-881B-EB04DEFE4E6EQ37014152-2D9ADDB1-F0B5-4D64-B530-BCCEFF932D60Q37022406-3EA59C7D-517A-4E9F-870A-AAD0A705049BQ37606583-2F751EB4-CFD4-4354-853B-DDC3D5A59AB3Q37637147-C435A99F-316C-46DF-AD17-2B8441F36DD9Q38123207-9F034CBF-6210-4314-B32E-8F5D81CBF045Q38152325-F3D12E61-2E70-4F34-ABB4-3244B3D8DCB9Q38227080-05615411-4F98-4F7B-BB13-1C0CEEAF209BQ38282823-5400B2FF-8DB8-4315-8BB4-3A49D7FA4F58Q38768316-EBD84B13-0FA7-48A9-89A7-3909E2319ECDQ38832323-8A718FBA-CC43-4360-B680-9A4B7A0CDB4FQ38846377-FECB3863-BDA6-4F97-A530-06678CD69947Q39281140-F37235FB-DBDC-4D5D-A908-74C8AF385779Q41914993-AACFE21F-DF19-41A8-AAC6-EE12717E5984Q42694688-7FE96E73-8A97-4212-81B6-DC76400A0C6EQ43044672-3464D46B-006A-4B1B-81D4-B4337E6CA5A0Q43557526-1FC4F160-5DD1-4A13-83C4-D2900032C1A7Q51751635-CA2BEEED-8EC4-4BA0-AA5C-7C24A38167F1Q53698370-0D679962-91F7-4CD5-9AD3-0176E6CC2B2BQ58796872-95FB285B-78E5-4B48-A88C-14653BD1932D
P2860
Molecular approaches to personalizing management of ovarian cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Molecular approaches to personalizing management of ovarian cancer.
@ast
Molecular approaches to personalizing management of ovarian cancer.
@en
type
label
Molecular approaches to personalizing management of ovarian cancer.
@ast
Molecular approaches to personalizing management of ovarian cancer.
@en
prefLabel
Molecular approaches to personalizing management of ovarian cancer.
@ast
Molecular approaches to personalizing management of ovarian cancer.
@en
P2860
P356
P1433
P1476
Molecular approaches to personalizing management of ovarian cancer.
@en
P2093
P2860
P304
viii5-viii15
P356
10.1093/ANNONC/MDR516
P478
22 Suppl 8
P577
2011-12-01T00:00:00Z